Drug Shortage Report for CEFUROXIME FOR INJECTION, USP
Report ID | 51497 |
Drug Identification Number | 02241639 |
Brand name | CEFUROXIME FOR INJECTION, USP |
Common or Proper name | Cefuroxime |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | CEFUROXIME |
Strength(s) | 1.5G |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS |
Packaging size | 1.5g |
ATC code | J01DC |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2018-06-01 |
Estimated end date | 2018-07-25 |
Actual end date | 2018-07-25 |
Shortage status | Resolved |
Updated date | 2018-07-26 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2018-07-26 | French | Compare |
v5 | 2018-07-26 | English | Compare |
v4 | 2018-07-04 | French | Compare |
v3 | 2018-07-04 | English | Compare |
v2 | 2018-06-05 | French | Compare |
v1 | 2018-06-05 | English | Compare |
Showing 1 to 6 of 6